Biogen, AbbVie yank MS drug Zinbryta off the market in the wake of encephalitis cases
The marketing effort for the MS drug Zinbryta (daclizumab) imploded today after European regulators flagged a lethal safety warning over cases of inflammatory encephalitis and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.